Cystic fibrosis mortality trend in Italy from 1970 to 2011

Journal of Cystic Fibrosis

Volumn 14, Issue 2, 2015, Pages 267-274

  Alicandro, Gianfranco ^a,b   Frova, Luisa ^a   Di Fraia, Gennaro ^a   Colombo, Carla ^b  

^a ITALIAN NATIONAL INSTITUTE OF STATISTICS   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Causes of deaths; Cystic fibrosis; Death certificates; Gender gap; Mortality

Indexed keywords

ADOLESCENT; ADULT; AMYLOIDOSIS; ARTICLE; CAUSE OF DEATH; CHILD; CHROMOSOME ABERRATION; COMORBIDITY; COMPARATIVE STUDY; CONGENITAL MALFORMATION; COR PULMONALE; CYSTIC FIBROSIS; DEATH CERTIFICATE; DIABETES MELLITUS; FEMALE; HUMAN; ITALY; KIDNEY FAILURE; LIVER DISEASE; LUNG ASPERGILLOSIS; LUNG CIRCULATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MALNUTRITION; MORTALITY; ORGAN TRANSPLANTATION; PNEUMONIA; RESPIRATORY TRACT DISEASE; SEPSIS; SEX DIFFERENCE; AGE; EPIDEMIOLOGY; INFANT; PRESCHOOL CHILD; SEX RATIO; SURVIVAL; TRENDS;

ADOLESCENT; ADULT; AGE FACTORS; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INFANT; ITALY; MALE; MORTALITY; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 84924298455     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.07.010     Document Type: Article

References (30)

1. Bossi A., Casazza G., Padoan R., Milani S. What is the incidence of cystic fibrosis in Italy? Data from the National Registry (1988-2001). Hum Biol 2004, 76:455-467.
2. Buzzetti R., Salvatore D., Baldo E., Forneris M.P., Lucidi V., Manunza D., et al. An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis. J Cyst Fibros 2009, 8:229-237.
3. Colombo C., Littlewood J. The implementation of standards of care in Europe: state of the art. J Cyst Fibros 2011, 10:S7-S15.
4. Barr H.L., Britton J., Smyth A.R., Fogarty A.W. Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study. BMJ 2011, 343:d4662.
5. Kulich M., Rosenfeld M., Goss C.H., Wilmott R. Improved survival among young patients with cystic fibrosis. Pediatr 2003, 142:631-636.
6. Rosenfeld M., Davis R., FitzSimmons S., Pepe M., Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997, 145:794-803.
7. Corey M., Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996, 143:1007-1017.
8. Assael B.M., Castellani C., Ocampo M.B., Iansa P., Callegaro A., Valsecchi M.G. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30years. Am J Epidemiol 2002, 156:397-401.
9. McIntyre K. Gender and survival in cystic fibrosis. Curr Opin Pulm Med 2013, 19:692-697.
10. Stern M., Wiedemann B., Wenzlaff P. From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995 2006. Eur Respir J 2008, 31:29-35.
11. Verma N., Bush A., Buchdahl R. Is there still a gender gap in cystic fibrosis?. Chest 2005, 128:2824-2834.
12. Dicker R., Coronado F., Koo D., Parrish R.G. Principles of epidemiology in public health practice. Atlanta, GA 30333: U.S. Department of health and human services 2006, 3-31. Centers for Disease Control and Prevention (CDC). Office of Workforce and Career Development. 3rd ed.
13. Breslow N.E., Day N.E. Statistical methods in cancer research. The Design and Analysis of Cohort Studies 1987, vol. 2. International Agency For Research On Cancer, World Health Organisation, Lyon.
14. Davis P.B. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006, 173:475-482.
15. Corey M., McLaughlin F.J., Williams M., Levison H. A comparison of survival growth and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988, 41:588-591.
16. Littlewood J.M., Kelleher J., Walters M.P., Johnson A.W. In vivo and in vitro studies of microsphere pancreatic supplements. J Pediatr Gastroenterol Nutr 1988, 7:S22-S29.
17. Ramsey B.W., Dorkin H.L., Eisenberg J.D., Gibson R.L., Harwood I.R., Kravitz R.M., et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993, 328:1740-1746.
18. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994, 331:637-642.
19. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176:957-969.
20. Liou T.G., Adler F.R., Fitzsimmons S.C., Cahill B.C., Hibbs J.R., Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153:345-352.
21. Buzzetti R., Alicandro G., Minicucci L., Notarnicola S., Furnari M.L., Giordano G., et al. Validation of a predictive survival model in Italian patients with cystic fibrosis. J Cyst Fibros 2012, 11:24-29.
22. Castellani C., Picci L., Tamanini A., Girardi P., Rizzotti P., Assael B.M. Association between carrier screening and incidence of cystic fibrosis. JAMA 2009, 302:2573-2579.
23. Sweezey N.B., Ratjen F. The cystic fibrosis gender gap: potential role of estrogen. Pediatr Pulmonol 2014, 49:309-317.
24. Viviani L., Bossi A., Assael B.M. Absence of a gender gap in survival. An analysis of the Italian registry for cystic fibrosis in the paediatric age. J Cyst Fibros 2011, 10:313-317.
25. Lai H.C., Kosorok M.R., Laxova A., Makholm L.M., Farrell P.M. Delayed diagnosis of US females with cystic fibrosis. Am J Epidemiol 2002, 156:165-173.
26. Pittman J.E., Calloway E.H., Kiser M., Yeatts J., Davis S.D., Drumm M.L., et al. Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease. Pediatr Pulmonol 2010, [published online ahead of print December 30, 2010]. 10.1002/ppul.21397.
27. Halliburton C.S., Mannino D.M., Olney R.S. Cystic fibrosis deaths in the United States from 1979 through 1991. An analysis using multiple-cause mortality data. Arch Pediatr Adolesc Med 1996, 150:1181-1185.
28. Colombo C., Setchell K.D., Podda M., Crosignani A., Roda A., Curcio L., et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990, 117:482-489.
29. Yahiaoui Y., Jablonski M., Hubert D., Mosnier-Pudar H., Noël L.H., Stern M., et al. Renal involvement in cystic fibrosis: diseases spectrum and clinical relevance. Clin J Am Soc Nephrol 2009, 4:921-928.
30. Maisonneuve P., Marshall B.C., Knapp E.A., Lowenfels A.B. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 2013, 105:122-129.